Tag: anti-PD-1

US expands reach of Keytruda in NSCLC

by Selina McKee | Nov 2, 2018 | News | 0

US regulators have approved MSD’s Keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Accelerated approval for Keytruda as combo for NSCLC

by Selina McKee | May 11, 2017 | News | 0

The US Food and Drug Administration has issued an accelerated approval for Merck & Co’s immunotherapy Keytruda in combination with pemetrexed (Eli Lilly’s Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.